Back to results
US 9,517,253 B2Granted
Compositions for treating multiple sclerosis
AssigneeTxcell
InventorArnaud Foussat
Life of this patent
Estimating the term…
Abstract
Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.
Claims9
A method for diminishing the loss of motor function and/or diminishing inflammation of the central nervous system in a human subject in need thereof, the method consisting of:
- administering to said subject an effective amount of a pharmaceutical composition consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen, in combination with one or more pharmaceutically acceptable carrier, or a medicament consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen,
- wherein said human multiple sclerosis-associated antigen is myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein, proteolipid protein, or a mixture thereof, and
- the pharmaceutical composition or medicament comprises Tr1cells autologous to the cells of the subject.
A method for diminishing the loss of motor function and/or diminishing inflammation of the central nervous system in a human subject in need thereof, comprising:
- administering to said subject an effective amount of a pharmaceutical composition consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen in combination with one or more pharmaceutically acceptable carrier, or a medicament consisting of a Tr1 cell population directed against at least one human multiple sclerosis-associated antigen,
- optionally in combination with one or more therapeutic agent used for treating multiple sclerosis,
- wherein said human multiple sclerosis-associated antigen is myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein, proteolipid protein, or a mixture thereof,
- said administration is without co-administration of the soluble antigen, and
- the medicament or pharmaceutical composition comprises Tr1 cells autologous to the cells of said subject.
2 more elements
Dependencies are inferred from the claim text.